홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

염산히드라라진

Hydralazine

HCID 3637
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
86-54-4
표준 SMILES
NNc1nncc2ccccc12
InChIKey
RPTUSVTUFVMDQK-UHFFFAOYSA-N
분자식
C8H8N4
평균 분자량
160.18 g/mol
단동위원소 질량
160.07489626

개요

Hydralazine is the 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent. It has a role as a vasodilator agent and an antihypertensive agent. It is a member of hydrazines, a member of phthalazines, an azaarene and an ortho-fused heteroarene.

이름 및 식별자

우선 이름
Hydralazine
IUPAC
phthalazin-1-ylhydrazine
현지명
염산히드라라진
영어명
Hydralazine
분자식
C8H8N4
분자량
160.18

이름 및 동의어

hydralazine1-Hydrazinylphthalazine86-54-41-Hydrazinophthalazinephthalazin-1-ylhydrazineHypophthalinAprezolinHydralazinApresolinHidralazinHydrazinophthalazineHidralazina
이름 더 보기
염산히드라라진히드랄라진c5968ba5968c-5068apressinciba5968NSC 126699apresoline
Idralazina1(2H)-Phthalazinone, hydrazone6-HydralazineHydrallazine1-PhthalazinylhydrazineHydralazinumPhthalazine, 1-hydrazino-Ciba 5968

데이터베이스 식별자

CAS
86-54-4
PubChem CID
3637
DTXSID
DTXSID4023129
ChEMBL
CHEMBL276832
ChEBI
CHEBI:5775
UNII
26NAK24LS8
EC Number
201-680-3
Nikkaji
J4.262E

물성

구조 계산 물성보충 중

XLogP
0.7
극성 표면적
63.8 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
4
회전 가능 결합 수
1
무거운 원자 수
12
형식 전하
0
복잡도
150

실험 및 물리화학적 성질

Chemical ClassesOther Uses -> Pharmaceuticals
Drugs · 2건

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP · 2건

0.7

1.0

Solubility · 2건

<1mg/mL

2.61e+00 g/L

Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Vasodilator Agents

Pharmaceuticals

Antihypertensive medicines

Melting Point · 2건

172-173 °C

172 - 173 °C

Physical DescriptionSolid
Dissociation Constants7.3
Collision Cross Section132.1 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 6건

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Danger

H317: May cause an allergic skin reaction [Warning Sensitization, Skin]

유해성 정보

Hazards SummaryAsthma and allergic contact dermatitis reported in pharmaceutical workers; [Malo] A skin sensitizer in the pharmaceutical industry; Patients often have cross-sensitivity with hydrazine; [Kanerva, p. 1155]
Hazard Classes and Categories · 2건

Acute Tox. 3 (100%)

Skin sensitization - Category 1

독성 정보

Hepatotoxicity · 1건

Serum aminotransferase elevations during hydralazine therapy are considered uncommon. However, hydralazine has been clearly linked to cases of acute liver injury with jaundice as well as a delayed lupus-like syndrome. Two clinical patterns of hepatic injury have been described, associated with either a short (2 to 6 weeks) or long (2 months to more than a year) latency period. The clinically apparent liver injury is usually hepatocellular, although cholestatic forms have also been reported (Case 1). In cases with a short latency period, rash, fever and eosinophilia are common and the onset is typically abrupt and severe, and recovery is rapid. In cases with a longer latency (Case 2), the onset is more typically insidious, liver biopsy may resemble chronic hepatitis and demonstrate fibrosis, and autoantibodies are often present. The late form of hepatitis may also accompany the lupus-like syndrome that occurs with hydralazine, particularly in high doses when given for 6 months or more. Recovery can be prolonged. Autoantibodies to isoforms of the P450 system (CYP 1A2) have been identified in patients with hepatotoxicity due to the structurally related antihypertensive agent dihydralazine (available in Europe, but not the United States) and which is associated with a higher rate of hepatotoxicity than hydralazine.

화학 및 산업

약리 정보

ATC Code · 3건

C - Cardiovascular system

QC - Cardiovascular system

C02DB02

Protein BindingHydralazine is 87% protein bound in serum likely to human serum albumin.
Pharmacodynamics · 1건

Hydralazine interferes with calcium transport to relax arteriolar smooth muscle and lower blood pressure. Hydralazine has a short duration of action of 2-6h. This drug has a wide therapeutic window, as patients can tolerate doses of up to 300mg. Patients should be cautioned regarding the risk of developing systemic lupus erythematosus syndrome.

Mechanism of Action · 1건

Hydralazine may interfere with calcium transport in vascular smooth muscle by an unknown mechanism to relax arteriolar smooth muscle and lower blood pressure. The interference with calcium transport may be by preventing influx of calcium into cells, preventing calcium release from intracellular compartments, directly acting on actin and myosin, or a combination of these actions. This decrease in vascular resistance leads to increased heart rate, stroke volume, and cardiac output. Hydralazine also competes with protocollagen prolyl hydroxylase (CPH) for free iron. This competition inhibits CPH mediated hydroxylation of HIF-1α, preventing the degradation of HIF-1α. Induction of HIF-1α and VEGF promote proliferation of endothelial cells and angiogenesis.

Biological Half-Life · 1건

Hydralazine has a half life of 2.2-7.8h in rapid acetylators and 2.0-5.8h in slow acetylators. The half life in heart failure patients is 57-241 minutes with an average of 105 minutes and in hypertensive patients is 200 minutes for rapid acetylators and 297 minutes for slow acetylators. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of pressure. However, other factors, such as acetylation being a minor metabolic pathway for hydralazine, will contribute to differences in elimination rates.

Metabolism/Metabolites · 2건

관련 반응

20건
반응 기록 만들기
HRID 261776 반응식
HRID 261776반응물로
HRID 492103 반응식
HRID 492103생성물로
HRID 492104 반응식
HRID 492104반응물로
HRID 492106 반응식
HRID 492106생성물로
HRID 702041 반응식
HRID 702041생성물로
HRID 952344 반응식
HRID 952344반응물로
HRID 1158224 반응식
HRID 1158224생성물로
HRID 1158225 반응식
HRID 1158225반응물로
이전1 / 3 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
녹는점
172 °C · 172°C
끓는 점
276.07 °C · 276.07°C (rough estimate)
밀도
1.2583 · 1.2583 (rough estimate)
굴절률
1.5872 · 1.5872 (estimate)
산도 계수 (pKa)
6.82 · pKa 6.820± 0.005(H2O,t = 25.0,Iundefined) (Uncertain)
물리적 상태
powder
수용성
4.8 mg/L · 4.8mg/L(22.5℃)
BCS Class
3 · 3
InChI
1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
InChIKey
RPTUSVTUFVMDQK-UHFFFAOYSA-N
SMILES
NNC1=C(C=CC=C2)C2=CN=N1
NIST
1 · 1(2H)-phthalazinone, hydrazone(86-54-4)
EPA
Hydralazine (86-54-4)

화학적 성질

Yiellow Solid

Adverse Effects · 2건

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

Hydralazine has been reported to cause headaches, nausea, flushing, hypotension, palpitations, tachycardia, dizziness, and angina.

Toxicity Summary · 1건

Published reports of toxicity with acute use of hydralazine are uncommon. Signs of toxicity include hypotension, tachycardia, headaches, and generalized flushing. Chronic toxicity could lead to DILE. There is no specific treatment for an overdose other than supportive therapy. Fluids should be given initially, followed by vasopressors if hypotension persists despite fluid resuscitation. Tachycardia or ischemia can be treated with beta-blockers with attention to blood pressure prior to administration.

Carcinogen Classification · 5건

Hydralazine

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 24: (1980) Some Pharmaceutical Drugs

1987

1987

Drug Induced Liver Injury · 5건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

hydralazine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

독성
LD50 in mice, rats (mg/kg): 122, 90 orally; 101, 40 i.p. (Dorigotti)
Hazard Classifications
Acute Tox. 3 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Acetylation is a minor metabolic pathway for hydralazine; the major pathway is hydroxylation followed by glucuronidation. There are 5 identified metabolic pathways for hydralazine. Hydralazine can be metabolized to phthalazine or α-ketoglutarate hydrazone. These metabolites can be further converted to phthalazinone or hydralazine can be metabolized directly to phthalazinone. Hydralazine can undergo a reversible converstion to the active hydralazine acetone hydrazone. Hydralazine is spontaneously converted to the active pyruvic acid hydrazone or the pyruvic acid hydrazone tricyclic dehydration product, and these metabolites can convert back and forth between these 2 forms. Hydralazine can be converted to hydrazinophthalazinone, which is further converted to the active acetylhydrazinophthalazinone. The final metabolic process hydralazine can undergo is the conversion to an unnamed hydralazine metabolite, which is further metabolized to 3-methyl-s-triazolophthalazine (MTP). MTP can be metabolized to 9-hydroxy-methyltriazolophthalazine or 3-hydroxy-methyltriazolophthalazine; the latter is converted to triazolophthalazine.

Hydralazine has known human metabolites that include hydralazine N-acetyl.

FDA Pharmacological Classification · 5건

26NAK24LS8

HYDRALAZINE

Physiologic Effects [PE] - Arteriolar Vasodilation

Established Pharmacologic Class [EPC] - Arteriolar Vasodilator

Hydralazine is an Arteriolar Vasodilator. The physiologic effect of hydralazine is by means of Arteriolar Vasodilation.

MeSH Pharmacological Classification · 2건

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and Excretion · 4건

Taking oral hydralazine with food improves the bioavailability of the drug. An intravenous dose of 0.3mg/kg leads to an AUC of 17.5-29.4µM\*min and a 1mg/kg oral dose leads to an AUC of 4.0-30.4µM\*min. The Cmax of oral hydralazine is 0.12-1.31µM depending on the acetylator status of patients.

<10% of hydralazine is recovered in the feces; 65-90% is recovered in the urine.

The volume of distribution is 1.34±0.79L/kg in congestive heart failure patients and 1.98±0.22L/kg in hypertensive patients.

The majority of hydralazine clearance is extrahepatic- 55% for rapid acetylators and 70% for slow acetylators. The average clearance in congestive heart failure patients is 1.77±0.48L/kg/h, while hypertensive patients have an average clearance of 42.7±8.9mL/min/kg.

Cellular LocationsMembrane

용도 및 제조

Uses · 2건

A Peripheral vasodilator used as an antihypertensive agent; [ChemIDplus]

Use (kg; approx.) in Germany (2009): >100

Use ClassificationPharmaceuticals

응용 분야

개요Cross-reactions between hydrazine derivatives occur. Hydralazine may sometimes cause flushing and reversible Lupus erythematosis

용도Hydralazine is a non-nucleoside analog that inhibits DNA methylation and reactivates the expression of tumor suppressor genes. Non-selective MAO-A/B inhibitor; semicarbazide-sensitive amine oxidase inhibitor. Antihypertensive.

상·하류 제품 정보

상류 원료

Phosphorus oxychloride염산프탈라존하이드라진, 모노수화물

하류 제품

히알루로니다제

추가 설명

정의ChEBI: The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.